Nutritional Factors Affecting Mental Health

Lim, So Young; Kim, Eun Jin; Kim, Arang; Lee, Hee Jae; Choi, Hyun Jin; Yang, Soo Jin

doi:10.7762/cnr.2016.5.3.143

Cited by 84 publications

(65 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, exposure to a ‘stressor’ does not inevitably cause stress. Deficiency in vitamin D, niacin, folate, vitamin B6, Vitamin B12 and omega‐3 fatty increase the susceptibility to stress and depression . Furthermore, polymorphisms of the glucocorticoid receptor gene are associated with basal cortisol secretion and increase the vulnerability to stress .…”

Section: Introductionmentioning

confidence: 99%

Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?

et al. 2017

View full text Add to dashboard Cite

SummaryDecades of research have reported only weak associations between the intakes of specific foods or drinks and weight gain and obesity. Randomized controlled dietary intervention trials have only shown very modest effects of changes in nutrient intake and diet composition on body weight in obese subjects. This review summarizes the scientific evidence on the role mental stress (either in or not in association with impaired sleep) may play in poor sleep, enhanced appetite, cravings and decreased motivation for physical activity. All these factors contribute to weight gain and obesity, possibly via decreasing the efficacy of weight loss interventions. We also review evidence for the role that lifestyle and stress management may play in achieving weight loss in stress-vulnerable individuals with overweight.

show abstract

Section: Introductionmentioning

confidence: 99%

Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Risk factors for dementia include a low educational level, advanced age, more than one comorbid condition, polypharmacy, gait impairment, cigarette smoking experience, depression and nutrition …”

Section: Introductionmentioning

confidence: 99%

Slow gait speed as a predictor of 1‐year cognitive decline in a veterans' retirement community in southern Taiwan

Hsu

Liang

Liao

et al. 2017

Geriatrics Gerontology Int

View full text Add to dashboard Cite

Aim: Slow gait speed has been associated with mortality, poor physical function and disability in older people. Our aim was to evaluate the association between slow gait speed and rapid cognitive decline among oldest-old men in Taiwan. Methods:We carried out a longitudinal cohort study in a veterans' retirement community, and enrolled 249 male residents aged 80 years and older. Slow gait speed was defined as <1 m/s, and rapid cognitive decline was defined as a Mini-Mental State Examination (MMSE) decline of ≥3 points over 1 year. Body mass index, Charlson's Comorbidity Index, handgrip strength, gait speed and Mini-Mental State Examination datasets were collected, and a logistic regression model was built to evaluate the association between fast cognitive decline and slow gait speed.Results: In all, 249 residents (mean age 86.4 ± 4.01 years) were recruited, including 58 (23.3%) with rapid cognitive decline. Univariate analysis showed that slow gait speed could predict rapid cognitive decline (OR 4.10, 95% CI 1.20-14.00, P = 0.024). After adjusting for age, Charlson's Comorbidity Index, polypharmacy, psychiatric drug usage, cigarette smoking experience, baseline cognitive function, depressive mood, handgrip strength, nutritional status and history of fall, slow gait speed was still independently associated with rapid cognitive decline (adjusted OR 4.58, 95% CI 1.22-17.2, P = 0.024).Conclusions: Slow gait speed was thus an independent predictor of rapid cognitive decline in oldest-old men in a veterans' retirement community in Taiwan.

show abstract

“…In this respect, our interest in intravenous infusion mode of delivery of potential drug lead in schizophrenia resembles the series of studies of intravenous infusion of ketamine in treatment resistant depression with comorbid suicidality [74,75]. Curcumin, however, distinguishes from ketamine and likely esketamine with its potential antipsychotic effects as shown in our study with oral formulation of curcumin as curcumin C-3 complex (66).…”

Section: Journal Of Clinical Epigenetics Issn 2472-1158mentioning

confidence: 87%

“…It remains to be seen whether the roadblocks in therapeutic advances in schizophrenia can To sum up, converging evidence provides the strong rationale for adopting the two-step paradigm shift in curcumin pharmaceutical development: 1) Transforming curcumin from crude spice and botanical extract to novel drug leads ; 2) in repurposing the liposome-based formulation: Lipocurc TM from oncology to CNS disorders including schizophrenia. In this respect, our interest in intravenous infusion mode of delivery of potential drug lead in schizophrenia resembles the series of studies of intravenous infusion of ketamine in treatment resistant depression with comorbid suicidality [74,75]. Curcumin, however, distinguishes from ketamine and likely esketamine with its potential antipsychotic effects as shown in our study with oral formulation of curcumin as curcumin C-3 complex (66).…”

mentioning

confidence: 90%

Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia?

Chiu¹,

Woodbury-Fariña²,

Terpstra³

et al. 2017

J Clin Epigenet

View full text Add to dashboard Cite

While pharmacotherapy of second generation of atypical antipsychotics: clozapine, olanzapine, risperidol, quetiapine, ziprasidone, aripiprazole bring about significant improvement in the positive symptoms of schizophrenia [1], overall psychosocial outcomes in schizophrenia remain modest. Significant functional impairment related to negative symptoms (lack of volition, apathy, sociality, poverty of speech and affective flattening), active positive symptoms (delusions, hallucinations and bizarre behavioral disturbances) and neuro-cognition deficits, persists in 20-30% of patients with schizophrenia refractory to AbstractDespite advances in pharmacotherapy, schizophrenia continues to carry a high societal disease burden related to positive and negative symptoms, and neurocognitive deficits and severe functional impairment. Findings from epigenetics have yet to translate the epigenetics targets to efficacious drug therapy. We review the repertoire of CNS pharmacology of curcumin derived from Curcuma Longa, commonly known as "turmeric": the well-known curry extract. We highlight the body of evidence in support of the emerging role of curcumin as a panhistone deacetylase (HDAC) inhibitor regulating the expression of genes involved in inflammation and NMDA N-methyl-aspartic acid (NMDA)-glutamate systems, as related to schizophrenia. Based on the findings from translational studies of curcumin extracts, curcumin C-3 complex formulation (Supercurcumin TM ) and patented liposome-based curcumin (Lipocurc TM ), we propose that intravenous infusion of Lipocurc TM holds promise as the novel drug lead and preferred targeted brain delivery mode in reprogramming faculty epigenetics network and in remodeling restrictive chromatin configuration in schizophrenia. Phase II/Phase III epigenetics-biomarker-based randomized placebo-controlled trials in treatment resistant schizophrenia are warranted. Our approach of intravenous infusion of Lipocurc TM behaving as pan HDAC inhibitor represents a new paradigm of drug development in combining targeting epigenetics footprints with brain-specific drug delivery system in schizophrenia. Lipocurc TM can open the Pandora box in unexplored therapeutics vistas in modifying the phenotype of treatment resistant schizophrenia. [2]. Major breakthroughs in schizophrenia therapeutics are yet forthcoming. It becomes imperative to design molecular genetics and epigenetic tools to predict treatment responses, and to translate novel CNS drug targets for accelerating the development of new therapeutics for treatment refractory schizophrenia. Drug platforms require refinement of translational models of schizophrenia to catalyze clinical trials and to predict treatment responses. In the post-genomic era, deciphering the epigenetic code of the human genomes represents a major challenge in CNS disorders. A growing body of evidence supports dysregulation of epigenetics signaling: DNA methylation, histone modifications and microRNA, plays a significant role in schizophrenia [3][4][5]. Findings from studies of p...

show abstract

Nutritional Factors Affecting Mental Health

Cited by 84 publications

References 78 publications

Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?

Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa?

Slow gait speed as a predictor of 1‐year cognitive decline in a veterans' retirement community in southern Taiwan

Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia?

Contact Info

Product

Resources

About